Published in Clin Pharmacol Ther on June 01, 1996
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol (2008) 2.36
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab (2008) 2.06
Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol (2000) 1.19
Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem. Front Genet (2013) 1.07
Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment. Cell Mol Neurobiol (1999) 0.91
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. Ann Pharmacother (2010) 0.88
Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1998) 0.83
Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide. Antimicrob Agents Chemother (1999) 0.82
Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B (2016) 0.78
Noninvasive assessment of liver function. Curr Opin Gastroenterol (2015) 0.78
Antipyrine clearance and metabolite formation in primary biliary cirrhosis. Dig Dis Sci (2001) 0.77
Effect of intermittent hypobaric hypoxia on efficacy & clearance of drugs. Indian J Med Res (2012) 0.77
The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol (2000) 0.76
Validation of the use of nonnaive surgically catheterized rats for pharmacokinetics studies. J Am Assoc Lab Anim Sci (2008) 0.75
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics (2001) 3.05
Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell (2000) 2.98
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem (2001) 2.62
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest (1999) 2.57
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet (1982) 2.19
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics (2001) 2.08
The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07
Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem (1995) 2.03
Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet (2001) 2.02
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther (2011) 1.98
Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature (1990) 1.96
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos (1996) 1.86
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol (1998) 1.83
Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg (2000) 1.71
Physiological disposition of verapamil in man. Cardiovasc Res (1976) 1.71
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther (2009) 1.67
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut (2003) 1.66
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics (1998) 1.64
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet (1991) 1.60
Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos (2001) 1.58
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol (1991) 1.57
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Polymorphic drug oxidation in humans. Fed Proc (1984) 1.53
Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain (1998) 1.52
An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation (1994) 1.52
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics (2001) 1.50
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther (2000) 1.48
Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr (1985) 1.46
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology (1996) 1.42
Is there a genetic factor in flecainide toxicity? BMJ (1988) 1.41
Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol (1984) 1.39
The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos (1979) 1.39
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol (1995) 1.39
The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J (1985) 1.35
Alkaline phosphatase activity and localization during the murine hair cycle. Br J Dermatol (1994) 1.34
Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest (1990) 1.30
Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol (1984) 1.30
The genetic polymorphism of sparteine metabolism. Xenobiotica (1986) 1.27
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27
The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.26
The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics (1994) 1.25
Drug metabolism in thyroid disease. Clin Pharmacokinet (1976) 1.24
Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol (1981) 1.23
Generation and cyclic remodeling of the hair follicle immune system in mice. J Invest Dermatol (1998) 1.22
Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21
Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. Eur J Clin Pharmacol (1984) 1.20
Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol (1985) 1.18
CYP3A genetics in drug metabolism. Nat Med (2001) 1.17
Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard. Arzneimittelforschung (1977) 1.17
Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment. Klin Wochenschr (1980) 1.16
Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.14
Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics (2000) 1.13
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features. J Inorg Biochem (2000) 1.11
Chlorinated hydrocarbons in adipose tissue of infants and toddlers: inventory and studies on their association with intake of mothers' milk. Eur J Pediatr (1984) 1.11
Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol (1981) 1.08
Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. Arch Biochem Biophys (1997) 1.08
Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics (2001) 1.06
Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol (1993) 1.06
Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther (1985) 1.05
The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol (2000) 1.04
Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics (1996) 1.04
MRI in tracheal stenosis by innominate artery in children. Pediatr Radiol (1991) 1.04
Ten statements on the motivation of medical teachers to teach. Med Teach (1992) 1.04
Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation (1989) 1.04
[On the metabolism of antipyrine (phenazone) in man (author's transl)]. Arzneimittelforschung (1978) 1.04
Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet (1985) 1.03
Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol (1987) 1.03
Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther (1985) 1.03
Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J (2001) 1.03
Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin Pharmacol Ther (1997) 1.02
Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr (1987) 1.00
Stereoselective protein binding of verapamil enantiomers. Biochem Pharmacol (1988) 1.00
Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol (1987) 0.99
"It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci (1995) 0.98
Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J (2007) 0.98
Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther (2001) 0.98
Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol (1989) 0.98
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet (1987) 0.98
High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem (2001) 0.97
Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry. J Inherit Metab Dis (2005) 0.96
Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets. Eur J Clin Pharmacol (1981) 0.96
Clusters of perifollicular macrophages in normal murine skin: physiological degeneration of selected hair follicles by programmed organ deletion. J Histochem Cytochem (1998) 0.96
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin Pharmacol (1986) 0.96
Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.95
A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol (1998) 0.95
HPLC determination of antipyrine metabolites. Pharmacology (1981) 0.95
Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today (2001) 0.95
Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol (1991) 0.95